124-Iodine Positron Emission Tomography/Computed Tomography Dosimetry in Pediatric Patients with Differentiated Thyroid Cancer
| Autor: | R J Marlowe, W W Koska, Markus Luster, Walter Jentzen, Lutz S. Freudenberg, A. Bockisch |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Male
Adolescent Endocrinology Diabetes and Metabolism Radiography Iodine Radioisotopes Thyroid carcinoma Endocrinology Internal Medicine medicine Humans Dosimetry Thyroid Neoplasms Child Lymph node Thyroid cancer Retrospective Studies medicine.diagnostic_test business.industry Thyroid Cancer Radiotherapy Dosage General Medicine medicine.disease medicine.anatomical_structure Positron emission tomography Lymphatic Metastasis Positron-Emission Tomography Female business Nuclear medicine |
| Zdroj: | Experimental and Clinical Endocrinology & Diabetes. 115:690-693 |
| ISSN: | 1439-3646 0947-7349 |
| Popis: | Aim: Publications on 124-iodine ( 124 I-)-positron emission tomography/computed tomography (PET/CT) dosimetry contain few if any data on pediatric patients with differentiated thyroid carcinoma (DTC). Aim of our study is to determine safety and informativeness of 124 I-PET/CT dosimetry in DTC patients ≤18yrs old. Material and Methods: We retrospectively analysed the data of 3 years of consecutive procedures (n-5) in children (n-4, 11-15 years). We acquired whole-body 124 I-PET emission data 4,24, 48, 72 and 96 hr, and 124 I-PET/CT data 25 hr after oral 124 I administration (22-26MBq). Using these data, we calculated the thyroid remnant or metastatic lesion dose in Gy per GBq of 131-iodine ( 131 I) (RDpA or LDpA, respectively). We measured with a well counter radiation counts of blood samples taken at 2, 4, 24, 48, 72 and 96 hr, and with an uncollimated Nal detector, whole-body clearance at approximately those times. Using these data, we calculated each patient's critical blood activity (CBA), the maximum 131 I activity avoiding the putative >2Gy blood dose portending serious myelotoxicity. Results: Besides hypothyroid fatigue, no symptoms were noted. In 4 dosimetry procedures before the first radioiodine therapy, RDpAs were generally high (median 288 Gy/GBq, range 59-648 Gy/GBq). LDpAs (4 lymph node metastases) were much lower (median 6.5 Gy/GBq, range 1-9Gy/ GBq). CBAs were high (median 26GBq, range 19-42, n=5). Disease management was modified or disease extent clarified in 2/4 patients. Conclusions: A standard adult 124 I-PET/CT dosimetry protocol appears to be safe and informative in pediatric DTC patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|